ASCO 2024: Focus on GI Oncology
ASCO 2024: Focus on GI Oncology
Advertisement
Kai-Keen Shiu, MD, PhDColorectal Cancer | June 18, 2024
Kai-Keen Shiu, MD, PhD, continues his discussion on neoadjuvant pembrolizumab for patients with colorectal cancer.
View More
Kai-Keen Shiu, MD, PhDColorectal Cancer | June 18, 2024
Dr. Shiu also discusses how the NEOPRISM-CRC study exceeded its primary endpoint with a high pCR rate.
Johnathan Ebben, MD, PhDBile Duct Cancer | June 12, 2024
Drs. Ebben and Uboha break down the importance of the QUIC study, a phase 2 investigation of first-line treatment of BTC.
Jennifer Knox, MDPancreatic Cancer | June 6, 2024
Dr. Knox details the early results of the PASS-01 trial, which looked at PDAC signature stratification for treatment.
Richard S. Finn, MDBile Duct Cancer | June 6, 2024
Richard Finn, MD, of University of California, Los Angeles, highlights 3-year follow-up data from KEYNOTE-966.
Peter R. Galle, MD, PhDUnresectable HCC | June 6, 2024
Dr. Galle shares the first results from CheckMate 9DW, a comparison of nivo/ipi against sorafenib or lenvatinib for uHCC.
Brandon TwyfordLiver Cancer | June 5, 2024
CheckMate 9DW trial: Nivolumab plus ipilimumab improves overall survival in unresectable hepatocellular carcinoma
Brandon TwyfordPancreatic Cancer | June 5, 2024
The trial compared mFOLFIRINOX vs gemcitabine/nab-paclitaxel in advanced PDAC.
Brandon TwyfordGastric Cancer | June 18, 2024
Phase 3 IKF-575/RENAISSANCE trial shows surgery after FLOT may benefit RPLN-only metastatic gastric cancer patients.
Emily MenendezGastric Cancer | June 5, 2024
Switch maintenance may extend the benefits of an initial treatment strategy and can delay clinical deterioration.
Filippo Pietrantonio, MDASCO 2024: Focus on GI Oncology | June 6, 2024
Drs. Filippo Pietrantonio and Nataliya Uboha continue their conversation with a review of the OS data from CodeBreaK 300.
Filippo Pietrantonio, MDGastric Cancer | June 6, 2024
Drs. Filippo Pietrantonio and Nataliya Uboha break down the results of the phase 3 ARMANI trial.
Benjamin L. Schlechter, MDColorectal Cancer | June 4, 2024
Dr. Schlechter also highlights how this research may effect long-term efficacy and durability of response in patients.
Benjamin L. Schlechter, MDColorectal Cancer | June 4, 2024
Dr. Schlechter discusses a phase 1 dose escalation study of a novel coupled CAR-T therapy for patients with mCRC.
Benjamin Weinberg, MD, FACPPancreatic Cancer | June 4, 2024
Dr. Weinberg explains the mechanism of action for BXCL701 and how it synergizes with pembrolizumab.
Kanwal Raghav, MBBS, MDColorectal Cancer | June 4, 2024
Dr. Raghav discusses ctDNA as an early predictor of treatment response in colorectal cancer.
Katy MarshallBile Duct Cancer | June 3, 2024
Treatment-related adverse events were mostly sitravatinib related and included hand-foot syndrome and hypertension.
Katy MarshallGastric Cancer | June 18, 2024
The primary end point of the analysis was OS, and secondary end points included PFS and ORR.
Brandon TwyfordColorectal Cancer | June 3, 2024
The phase 3 trial examined the effects of TNT with LCRT and CAPOX on outcomes in high-risk locally advanced rectal cancer.
Emily MenendezPancreatic Cancer | June 3, 2024
GABARNANCE compared the use of gemcitabine plus nab-paclitaxel with concurrent chemoradiotherapy with S-1.
Advertisement
Advertisement
Advertisement
Latest News

July 12, 2024